Table 3.
SARS-CoV-2 candidate vaccines in clinical evaluation (July 20, 2020).
| Vaccine, sponsor/enrollment age | Study identifier number (phase, country/estimated first results) |
|---|---|
| Vector-based vaccines | |
| ChAdOx1 nCoV-19 (Oxford University); genetically altered adenovirus expressing the SARS-CoV-2 spike protein/18 to 55 years | ISRCTN89951424 (ph 3, Brazil)/July, 2021NCT04324606 (ph 1-2, United Kingdom)/May, 2021 |
| Ad5-nCoV (Beijing Institute of Biotechnology, CanSino Biologics Inc); adenovirus type-5 vectored vaccine expressing SARS-CoV-2 full-length spike protein/18 to 60 years | NCT04341389 (ph 2, China)/January, 2021NCT04313127 (ph 1, China)/December, 2020 |
| Gam-COVID-Vac (Gamaleya Research Institute, Health Ministry of the Russian Federation); adenoviral-based vaccine/18 to 60 years | NCT04436471 (ph 1, Russian Federation/August, 2020 |
| Gam-COVID-Vac Lyo (Gamaleya Research Institute, Health Ministry of the Russian Federation/Accellena Research); lyophilizate adenoviral-based vaccine/18 to 60 years | NCT04437875 (Phase 1-2, Russian Federation/August, 2020 |
| LV-SMENP-DC vaccine (Shenzhen Geno-Immune Medical Institute); lentiviral vector system (NHP/TYF) expressing viral proteins and immune modulatory genes to modify dendritic cells (DCs) and to activate T cells/6 months to 80 years |
NCT04276896 (DC vaccine + LV-SMENP-DC) (ph 1-2, China)/July, 2023 |
| SARS-CoV-2 aAPC Vaccine (Shenzhen Geno-Immune Medical Institute); NHP/TYF expressing viral proteins and modified artificial antigen-presenting cell (APC) to reactivate T cells/6 months to 80 years |
NCT04299724 (ph 1, China) /July, 2023 |
| Nucleic acid vaccines | |
| mRNA-1273 (NIAID); lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine encoding full-length, spike protein of SARS-CoV-2/18 to 99 years |
NCT04283461 (ph 1, SUA) /November, 2021 |
| mRNA-1273 (mRNA-1273 + Placebo) (Moderna TX Inc, Biomedical Advanced Research and Development Authority); two dose levels of mRNA-1273 versus placebo/18 years and older |
NCT04405076 (ph 2-3, SUA) /March, 2021 |
| BNT162, (BioNTech Pharmaceuticals GmbH); Dose-Escalation Trial of four RNA vaccine candidates combined with a lipid nanoparticle formulation (LNP) (different dosing regimens)/18 to 55 years |
NCT04380701 (ph 1-2, Germany) /August, 2020 |
| BNT162 (BioNTech, Pfizer); LNP-mRNAs (different dosing regimens)/18 to 85 years | NCT04368728 (ph 1-2, SUA, Germany)/June, 2021 |
| INO-4800 + electroporation using CELLECTRA 2000 (Inovio Pharmaceuticals, CEPI);DNA plasmid encoding S protein delivered by electroporation with CELLECTRA® 2000)/intradermal DNA vaccine/18 years and older | NCT04336410 (ph 1 SUA, ph 2 USA)/July 2021 |
| INO-4800 +electroporation using CELLECTRA 2000 (International Vaccine Institute, CEPI, Inovio Pharmaceuticals)/19 to 64 Year | NCT04447781 (ph1-2, Republic of Korea)/February 2022 |
| GX-19 (Genexine,Inc); DNA vaccine expressing SARS-CoV-2 S-protein antigen/18 to 50 Years | NCT04445389 (ph1-2, Republic of Korea/March, 2021 |
Resources: U.S. National Library of Medicine https://clinicaltrials.gov International Clinical Trials Registry Platform (ICTRP)/ https://www.isrctn.com/.